Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department

NCT07765030 | Not Yet Recruiting

• 1 other identifier: 13/45
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026. Medical records will be reviewed to collect information on patient demographics, comorbidities, clinical findings at admission, vital signs, renal replacement therapy indications, laboratory results before and after treatment, treatment modality, treatment-related complications, need for intubation or vasopressor/inotropic support, intensive care unit admission, length of stay, and hospital outcomes. The primary outcome is in-hospital mortality. Secondary outcomes include emergency department mortality, intensive care unit admission, ward admission, discharge status, emergency department and hospital length of stay, need for intubation or vasopressor/inotropic support, treatment completion, treatment-related complications, and changes in laboratory parameters before and after renal replacement therapy. No additional intervention, test, treatment, or biological sample collection will be performed as part of this study.

Conditions

Acute Kidney Injury; Kidney Failure, Acute; Kidney Failure

Keywords

Emergency Renal Replacement Therapy; Hemodialysis; Continuous Venovenous Hemodiafiltration; Acute Kidney Injury; In-Hospital Mortality

Outcome Measures

Primary Outcomes (1)

• In-Hospital Mortality

  Number and proportion of patients who die during the index hospitalization following emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF).

  Up to 30 days from emergency department admission

Secondary Outcomes (3)

• Emergency Department Mortality

  Up to 1 day from emergency department admission

• Intensive Care Unit Admission

  Up to 1 day from emergency department admission

• Renal Replacement Therapy-Related Complications

  Up to 8 hours from emergency department admission

Study Arms (2)

Hemodialysis (HD) Group

Critically ill adult patients who underwent hemodialysis (HD) in the emergency department for an emergency renal replacement therapy indication during the study period.

Procedure: Hemodialysis (HD); Procedure: Continuous Venovenous Hemodiafiltration (CVVHDF)

Continuous Venovenous Hemodiafiltration (CVVHDF) Group

Critically ill adult patients who underwent continuous venovenous hemodiafiltration (CVVHDF) in the emergency department for an emergency renal replacement therapy indication during the study period.

Procedure: Hemodialysis (HD); Procedure: Continuous Venovenous Hemodiafiltration (CVVHDF)

Interventions

Hemodialysis (HD) PROCEDURE

Hemodialysis performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.

Continuous Venovenous Hemodiafiltration (CVVHDF) Group; Hemodialysis (HD) Group

Continuous Venovenous Hemodiafiltration (CVVHDF) PROCEDURE

Continuous venovenous hemodiafiltration performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.

Continuous Venovenous Hemodiafiltration (CVVHDF) Group; Hemodialysis (HD) Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of critically ill adult patients aged 18 years or older who were managed in the critical care area of the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026, and who underwent emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF). All eligible patients meeting the predefined inclusion and exclusion criteria during the study period will be included using a census sampling approach. Data will be obtained retrospectively from the hospital information management system, electronic medical records, laboratory records, renal replacement therapy records, and clinical follow-up notes. No direct participant recruitment or contact will occur.

You may qualify if:

• Age 18 years or older.
• Followed in the critical care area of the Emergency Department of Antalya
• Training and Research Hospital between January 1, 2023, and August 1, 2026.
• Presence of an indication for emergency renal replacement therapy.
• Underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the emergency department.
• Required critical care-level monitoring or management.
• Availability of sufficient demographic, clinical, laboratory, and in-hospital outcome data in the hospital information system, electronic medical records, laboratory records, or clinical follow-up notes.

You may not qualify if:

• Age younger than 18 years.
• Renal replacement therapy initiated outside the emergency department.
• Presentation only for routine chronic hemodialysis at the hospital dialysis unit without receiving renal replacement therapy in the emergency department.
• Renal replacement therapy planned in the emergency department but HD or CVVHDF could not be performed.
• Missing essential clinical, laboratory, or in-hospital outcome data. In patients with repeated emergency department admissions, only the first emergency renal replacement therapy episode will be included to reduce statistical dependency.

Sponsors & Collaborators

• Antalya Health Sciences University: lead

Study Sites (1)

University of Health Sciences, Antalya Training and Research Hospital

Antalya, konyaaltı, 21090, Turkey (Türkiye)

Location

Related Publications (2)

• Kim JE, Jeong J, Choi Y, Moon HJ. Utilization of Renal Replacement Therapy and Its Impact on the Emergency Department Length of Stay in South Korean Emergency Medical Centers. Medicina (Kaunas). 2026 Jul 1;62(7):1273. doi: 10.3390/medicina62071273.

  PMID: 42512815 BACKGROUND

• Meersch-Dini M, Abu-Tair M, Bayer M, Brinkmann A, Bellmann R, Brunkhorst F, Custodis F, Czock D, Frey O, Galle J, Hermes C, Joannidis M, John S, Jorres A, Kerz T, Kindgen-Milles D, Koczor M, Kram R, Kuhlmann M, Oppert M, Schlieper G, Schmitz M, Zarbock A, Willam C. Multidisciplinary guidelines on renal replacement therapy in intensive care medicine. Crit Care. 2026 Jan 14;30(1):46. doi: 10.1186/s13054-025-05817-6.

  PMID: 41535952 BACKGROUND

MeSH Terms

Conditions

Acute Kidney Injury; Renal Insufficiency

Interventions

Renal Dialysis; Continuous Renal Replacement Therapy

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Renal Replacement Therapy; Therapeutics; Sorption Detoxification; Extracorporeal Circulation; Surgical Procedures, Operative

Central Study Contacts

murat Duyan, ASSOCIATE PROFESSOR

CONTACT

+90 540 412 0735; drmuratduyan@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 7, 2026
• First Posted: August 14, 2026
• Study Start: August 10, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: August 14, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)